The global kidney cancer drugs market is complex in nature owing to the involvement of various products and combination therapies targeting different stages of renal cell carcinoma. Kidney or renal cell carcinoma (RCC) is the most common type of kidney cancer in adults. Renal cell carcinoma begins in the renal tubular epithelial cells and accounts for approximately 90% of kidney cancers. Drugs...
English
Français
Español
Português
Deutsch
Türkçe
Dutch
Italiano
Russian
Romaian